The Drug Enforcement Administration (DEA) is considering three company applications involving the importation of tetrahydrocannabinols and the manufacture of marijuana, marijuana extracts and synthetic THC.

The applications were disclosed in Federal Register notices filed today and scheduled for publication August 26.

Experic LLC, based in Cranbury, New Jersey, applied to import Schedule I tetrahydrocannabinols for internal research and clinical trial purposes. The company is also seeking authorization to import 5-MeO-DMT and the synthetic cannabinoid medication nabilone.

DEA said the registration would not authorize Experic to import finished dosage forms, whether approved or unapproved by the Food and Drug Administration, for commercial sale.

Chemtos LLC, based in Round Rock, Texas, applied to become a bulk manufacturer of marijuana, marijuana extract, tetrahydrocannabinols and numerous other controlled substances. The company plans to manufacture the substances for distribution to customers as reference standards, which are highly characterized materials commonly used in laboratory testing and research.

The Chemtos application also covers an extensive list of synthetic cannabinoids, psychedelics, stimulants, opioids and other Schedule I and Schedule II substances.

Cambrex Charles City, an Iowa-based pharmaceutical manufacturing company, separately applied to manufacture tetrahydrocannabinols in bulk. The company specified that the THC would be synthetic.

Cambrex said it plans to manufacture the listed substances for conversion into other controlled substances and for sale to customers conducting dosage-form development, clinical trials and stability qualification studies. Its application also includes amphetamine, fentanyl, oxycodone and several other Schedule II substances.

The notices do not indicate that DEA has approved the applications. Existing registered manufacturers and applicants may submit comments, objections or hearing requests before the applicable deadlines following publication.